Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -4,453,081 | -23,058,135 | -13,292,769 | -49,132,094 |
| Amortization | 30,417 | 30,074 | 29,737 | 87,315 |
| Warrant inducement expenses (note 10) | NaN | NaN | -334,940 | 33,856,814 |
| Stock-based compensation | 757,484 | 881,150 | 1,820,555 | 7,077,332 |
| Loss from change in fair value of promissory notes | -2,495,400 | 6,743,736 | 335,581 | 5,739,005 |
| Gain on extinguishment of debt | 285,600 | NaN | NaN | NaN |
| Gain from change in fair value of warrant liability | -6,838,022 | 2,791,813 | -2,682,686 | -40,333,145 |
| Loss on equity method investment | -45,119 | -38,634 | -40,419 | -100,588 |
| Accounts receivable | 2,605,219 | -1,376,322 | -260,491 | 1,751,422 |
| Inventory | -113,822 | 119,660 | -788,312 | 4,126,716 |
| Prepaid expenses and other current assets | 2,176,011 | 439,855 | -1,840,783 | -6,171,166 |
| Other assets | NaN | NaN | 1 | 95,246 |
| Operating lease liabilities | -15,238 | -13,499 | -13,007 | -37,124 |
| Accounts payable | 5,706,232 | -2,873,739 | 30,255 | 1,635,794 |
| Accrued expenses | 4,387,442 | -295,952 | 354,702 | 1,355,493 |
| Income taxes payable | NaN | NaN | -1,554,629 | NaN |
| Net cash used in operating activities | -7,828,055 | -14,939,111 | -12,377,197 | -39,452,240 |
| Proceeds from the sale of common stock and warrants to purchase common stock | 6,898,857 | 14,931,536 | 8,085,009 | 17,311,389 |
| Proceeds from exercise of common stock warrants | 0 | 601,914 | 5,800,040 | 16,831,132 |
| Proceeds from debt | 17,000,000 | NaN | 0 | 33,100,000 |
| Repayment of debt | 17,000,000 | NaN | 2,325,581 | 33,817,005 |
| Net cash provided by financing activities | 6,898,857 | 15,533,450 | 11,559,468 | 33,425,516 |
| Net decrease in cash and cash equivalents | -929,198 | 594,339 | -817,729 | -6,026,724 |
| Cash and cash equivalents at beginning of period | 8,677,424 | 8,083,085 | 14,927,538 | NaN |
| Cash and cash equivalents at end of period | 7,748,226 | 8,677,424 | 8,083,085 | NaN |